Allogene Therapeutics Inc (ALLO)
2.755
0.00 (0.00%)
USD |
NASDAQ |
May 01, 10:30
Allogene Therapeutics Research and Development Expense (Quarterly): 54.66M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 54.66M |
| September 30, 2023 | 45.98M |
| June 30, 2023 | 62.04M |
| March 31, 2023 | 80.24M |
| December 31, 2022 | 75.42M |
| September 30, 2022 | 63.64M |
| June 30, 2022 | 57.17M |
| March 31, 2022 | 60.16M |
| December 31, 2021 | 53.98M |
| September 30, 2021 | 58.72M |
| June 30, 2021 | 52.29M |
| March 31, 2021 | 55.18M |
| Date | Value |
|---|---|
| December 31, 2020 | 52.23M |
| September 30, 2020 | 51.42M |
| June 30, 2020 | 47.30M |
| March 31, 2020 | 42.04M |
| December 31, 2019 | 49.36M |
| September 30, 2019 | 40.00M |
| June 30, 2019 | 31.77M |
| March 31, 2019 | 23.40M |
| December 31, 2018 | 18.50M |
| September 30, 2018 | 10.87M |
| June 30, 2018 | 122.49M |
| March 31, 2018 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
31.77M
Minimum
Jun 2019
80.24M
Maximum
Mar 2023
54.40M
Average
53.98M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Agenus Inc | -- |
| ANI Pharmaceuticals Inc | 9.867M |
| Vaxart Inc | 14.70M |
| aTyr Pharma Inc | 12.76M |
| PAVmed Inc | 3.595M |